List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 14 studies with search of: "Amikacin"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia
Condition: Pneumonia
Interventions: Drug: ceftazidime and amikacin;   Drug: ceftazidime and amikacin
2 Recruiting Pharmacokinetics of Nebulized Amikacin in Patients With Pneumonia Undergoing Mechanical Ventilation
Condition: Ventilator Associated Pneumonia
Interventions: Drug: Nebulized amikacin;   Drug: Intravenous amikacin;   Drug: Placebo nebulization;   Drug: Placebo infusion
3 Completed A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.
Conditions: Mycobacterium Avium-Intracellulare Infection;   HIV Infections
Interventions: Drug: Ciprofloxacin hydrochloride;   Drug: Ethambutol hydrochloride;   Drug: Amikacin sulfate;   Drug: Azithromycin;   Drug: Rifampin;   Drug: Clofazimine
4 Withdrawn Amikacin Penetration Into the Cerebrospinal Fluid
Conditions: Gram Negative Meningitis;   Post Traumatic Bacterial Meningitis
Intervention: Drug: Systemic and Intra-Thecal Amikacin Therapy
5 Completed Once-Daily Amikacin Plus Cloxacillin in Febrile Neutropenic Children
Conditions: Neutropenia;   Cancer;   Fever
Intervention: Drug: cloxacillin and amikacin (once or twice daily dosage)
6 Not yet recruiting Inhaled Amikacin Solution (BAY41-6551) as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
Condition: Pneumonia
Interventions: Drug: Amikacin (BAY41-6551);   Drug: Aerosolized Placebo
7 Completed Antiseptic Use and Dressing Application
Conditions: Skin Colonization;   Catheterization;   Bacterial Infection
Interventions: Procedure: disinfection efficacy using Biseptine;   Procedure: disinfection efficacy using Amukin
8 Completed A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
Conditions: HIV Infections;   Tuberculosis
Interventions: Drug: Cycloserine;   Drug: Ethionamide;   Drug: Capreomycin sulfate;   Drug: Aminosalicylic acid;   Drug: Streptomycin sulfate;   Drug: Ethambutol hydrochloride;   Drug: Amikacin sulfate;   Drug: Isoniazid;   Drug: Pyrazinamide;   Drug: Pyridoxine hydrochloride;   Drug: Levofloxacin;   Drug: Rifampin;   Drug: Clofazimine
9 Completed A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections
Condition: Infection
Interventions: Drug: Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.;   Drug: Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited;   Drug: Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.;   Drug: Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.
10 Completed Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)
Conditions: Cystic Fibrosis;   Chronic Bronchitis
Interventions: Drug: IV amikacin;   Drug: PO azithromycin;   Drug: IV ceftazidime;   Drug: PO ciprofloxacin;   Drug: IV meropenem;   Drug: IV piperacillin-tazobactam;   Drug: IV ticarcillin-clavulanate;   Drug: IV tobramycin
11 Active, not recruiting Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)
Condition: Cystic Fibrosis
Intervention: Drug: Arikace™
12 Completed A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit
Conditions: Infection;   Pneumonia
Interventions: Drug: MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days;   Drug: Comparator: amikacin / Duration of Treatment: 3 Days;   Drug: Comparator: tazocin / Duration of Treatment: 3 Days;   Drug: Comparator: vancomycin / Duration of Treatment: 3 Days
13 Active, not recruiting A Study to Determine the Safety and Tolerability of Arikace™ Versus Placebo in Patients Who Have Bronchiectasis.
Condition: Bronchiectasis
Interventions: Drug: Arikace 280 mg;   Drug: Arikace 560 mg;   Drug: Matching Placebo
14 Active, not recruiting Multidose Safety and Tolerability Study of (Arikace™) for Inhalation In Cystic Fibrosis Patients
Condition: Cystic Fibrosis
Intervention: Drug: Arikace™

Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services